Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | CDK2 | P24941 | 11/20 | 0.56 |
| ▸ | CDK1 | P06493 | 6/20 | 0.56 |
| ▸ | AURKA | O14965 | 3/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076031 | 0.90 | MEN1 (0.59) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL2073699 | 0.89 | CDK2 (0.53) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL2283576 | 0.87 | CDK2 (0.59) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL2076824 | 0.85 | CDK2 (0.57) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL2075784 | 0.85 | CDK2 (0.72) | MEN1MAPTKMT2ALMNACDK2 | |
| SCHEMBL2073788 | 0.85 | CDK2 (0.62) | MEN1MAPTKMT2AALDH1A1GAA | |
| SCHEMBL2286476 | 0.82 | CDK2 (0.74) | CDK2CDK1AURKAAURKBFLT3 | |
| SCHEMBL2073696 | 0.82 | CDK2 (0.61) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL4803155 | 0.82 | CDK2 (0.71) | CDK2CDK1AURKAAURKBFLT3 | |
| SCHEMBL2283519 | 0.80 | CDK2 (0.56) | MEN1MAPTKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| CN-1711258-A | Pyrimidine compounds | CYCLACEL LTD (GB) | 2005-12-21 | — | — | CN | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | MEN1 3957/4885MAPT 1954/4885KMT2A 1224/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | MEN1 3957/4885MAPT 1954/4885KMT2A 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.